Patents by Inventor Mingzhan Xue

Mingzhan Xue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hesperetin and trans-resveratrol compositions and methods thereof
    Patent number: 11135145
    Abstract: The invention relates to a composition, in particular to an oral anti-ageing composition for treating hair ageing. This invention is based on the observation that the combination of hesperetin, a flavanone, derivable from a natural rutinoside hesperetin 7-rutinoside (also known as hesperidin) in citrus, e.g., in Citrus aurantium L, Citrus sinensis, Zanthozylum gilletti, leaves of Agathosma serratifolia, and trans-resveratrol synergistically up-regulates NQO-1 in a gene expression assay. The combination also induces Glo1, decreases MG and MG-protein glycation, decreases insulin resistance, decreases fasting plasma glucose, induces modest weight loss, improves renal function, decreases vascular inflammation marker slCAM-1, improves arterial dilatation and decreases the risk of cardiovascular disease.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: October 5, 2021
    Inventors: Paul John Thornalley, Naila Rabbani, Mingzhan Xue
  • COMPOSITION FOR HAIR FOLLICLE GROWTH
    Publication number: 20180344603
    Abstract: The invention relates to a composition, in particular to an oral anti-ageing composition for treating hair ageing. This invention is based on the observation that the combination of hesperetin, a flavanone, derivable from a natural rutinoside hesperetin 7-rutinoside (also known as hesperidin) in citrus, e.g., in Citrus aurantium L, Citrus sinensis, Zanthozylum gilletti, leaves of Agathosma serratifolia, and trans-resveratrol synergistically up-regulates NQO-1 in a gene expression assay. The combination also induces Glo1, decreases MG and MG-protein glycation, decreases insulin resistance, decreases fasting plasma glucose, induces modest weight loss, improves renal function, decreases vascular inflammation marker slCAM-1, improves arterial dilatation and decreases the risk of cardiovascular disease.
    Type: Application
    Filed: November 7, 2016
    Publication date: December 6, 2018
    Applicant: CONOPCO, INC., d/b/a UNILEVER
    Inventors: Mark Ian Fowler, Gail Jenkins, David James Messenger, Naila Rabbani, Paul John Thornalley, Mingzhan Xue
  • Prevention of proteomic and genomic damage by dicarbonyl substrates of Glo 1
    Patent number: 9351951
    Abstract: The invention concerns the role of Glo 1 in the prevention and reversal of proteomic and genomic damage by carbonyl substrates thereof and, in particular, therapeutics that promote Glo 1 production.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: May 31, 2016
    Assignee: University of Warnick
    Inventors: Mingzhan Xue, Paul Thornalley, Naila Rabbani
  • PREVENTION OF PROTEOMIC AND GENOMIC DAMAGE BY DICARBONYL SUBSTRATES OF GLO 1
    Publication number: 20130231387
    Abstract: The invention concerns the role of Glo 1 in the prevention and reversal of proteomic and genomic damage by carbonyl substrates thereof and, in particular, therapeutics that promote Glo 1 production.
    Type: Application
    Filed: June 20, 2011
    Publication date: September 5, 2013
    Applicant: THE UNIVERSITY OF WARWICK
    Inventors: Mingzhan Xue, Paul Thornalley, Naila Rabbani